Curated News
By: NewsRamp Editorial Staff
December 29, 2024
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. for Q3 2024
Discuss on Reddit
Substack
Telegram
GithubTLDR
- Bio-Path Holdings, Inc. raised $4.0M for operational plans, showcasing strong drug pipeline undervalued compared to peers.
- Bio-Path utilizes proprietary DNAbilize® technology for antisense DNA therapeutics, advancing clinical trials with favorable safety profiles.
- Bio-Path's breakthrough technology offers potential cancer treatments, forming strategic relationships to advance drug development and improve patient outcomes.
- Bio-Path's innovative drug candidates in clinical trials show promise for treating various cancers, with potential applications for obesity-related conditions.
Impact - Why it Matters
This news highlights Bio-Path Holdings' innovative approach to cancer treatment, showcasing its promising drug candidates and breakthrough technology. The company's strong IP position and strategic relationships position it as a key player in the biopharmaceutical industry, with potential for significant growth and advancements in cancer therapeutics.
Summary
Bio-Path Holdings, Inc. (Nasdaq:BPTH) receives updated coverage from Stonegate Capital Partners for Q3 2024, highlighting recent private placement funding of $4.0M to support ongoing clinical trials for its innovative drug candidates, including prexigebersen, BP1001-A, BP1002, and BP1003. The company's proprietary technology, DNAbilize®, aims to revolutionize DNA drug delivery with promising results in cancer treatment. With strong IP protection and strategic relationships with leading cancer centers, Bio-Path is poised for success in the biopharmaceutical industry.
Source Statement
This curated news summary relied on this press release disributed by Reportable. Read the source press release here, Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. for Q3 2024
